From 10,000 yuan to 1,000 yuan, the orthopedic spine consumables market may face a reshuffle

【Pharmaceutical Network Market Analysis】Following the coronary stent and artificial joint, the third batch of high-value medical consumables collected by the national organization that has attracted much attention in the industry has also produced the results of the proposed selection at the end of September this year
.
According to the needs of cervical and thoracic and thoracic lumbar spine surgery, the collection covers 5 kinds of orthopedic spine consumables of cervical spine fixation fusion, thoracolumbar spine fixation fusion, vertebral body plasty, endoscopic nucleus medullary removal, and artificial disc replacement, forming 14 product system categories
.
The results of the proposed selection show that a total of 152 enterprises are to be selected, and the average price of the products to be selected is reduced by 84%, which is expected to save 26 billion yuan
per year.
Some products have dropped in price significantly, from 10,000 yuan to 1,000 yuan, such as the average price per set of thoracolumbar posterior fixed fusion consumables from 33,000 yuan to less than 10,000 yuan, the price is about 4,500 yuan, and the average price of some large foreign-funded brands per set has also dropped from 60,000 yuan to about 4,800 yuan; the average price of thoracolumbar minimally invasive surgical consumables has dropped from nearly 40,000 yuan to about 5,600 yuan; for example, the average price of each set of vertebral plastyling surgical consumables has dropped from 27,000 yuan to about
1,100 yuan 。 It is reported that the third batch of high-value medical consumables collection plan of the state organization will be implemented throughout the country in February next year, when patients are expected to use the consumables products
that have reduced prices 。 The frequent blowing of the collection policy is undoubtedly a great gospel for patients, and it is also conducive to rectifying the inflated prices and unhealthy trends in the high-value consumables industry, so what kind of impact has it had on enterprises? Judging from the results of the selection of consumables, the enterprises to be selected include domestic enterprises such as Weigao Orthopedics, Dabo Medical, Sanyou Medical, Mindray Medical, Chunli Medical, etc.
, as well as imported manufacturers such as Johnson & Johnson, Melito, and B.
Braun, which can fully meet clinical needs
.
The industry believes that the average decline of 84% results significantly exceeded market expectations, but it is conducive to squeezing out the inflated water, and further promoting the substitution of domestic brands for foreign brands, rewriting the past situation in
which foreign brands occupied the market share of major orthopedic spine consumables in China.
For the selected enterprises, in general, there is a guarantee of sales volume, and some "barefoot" enterprises will even have more volumes
.
For the failed bidder, it may adversely affect the performance, and the winning bidder will also face the risk of a sharp decline in the terminal price of
the product in the short term.
However, in the long run, the concentration of the industry is expected to be continuously improved, which is good for the head companies
with complete product pipelines, strong research and development strength and certain brand power in the orthopedic track.
In order to cope with the risk of collection, in this year's semi-annual report, some listed companies have stated that they will take certain measures
.
For example, Sanyou Medical said in the semi-annual report that the company will actively respond to spine collection, strengthen production and operation and refined management, and enhance the company's product innovation ability and comprehensive strength; Weigao Orthopedics said that it will combine the market, technology development trends and clinical feedback, continue to explore the layout of new materials, new fields and new technologies, gradually improve the layout of orthopedic upstream and downstream industries, open up new fields of orthopedics, and find new profit growth points; Dabo Medical also mentioned that it will adjust its business strategy in a timely manner and actively respond to the changes brought about by the
reform of high-value medical consumables.
In the secondary market, some orthopedic listed companies were affected by the results of the collection, and the stock price rose by more than 10% on the same day, which fully reflected the market's better
expectations for the industry.
As of the close of trading on September 28, Dabo Medical rose 10%, quoted 33.
22 yuan, turnover of 227 million, turnover rate of 2.
03%, P/E (TTM) 25.
85; Weigao Orthopedics quoted 57.
50 yuan, an increase of 5.
82%, turnover of 124 million, turnover rate of 4.
24%, P/E (TTM) 31.
98
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.